Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database

CONCLUSION: PARPis increased the risk of pneumonitis that can result in serious outcomes and tend to occur early. Early recognition and management of PARPi-pneumonitis is of vital importance in clinical practice. The mechanisms and risk factors should be studied further to improve clinical understanding and innovative treatment strategies for these diseases.PMID:34023129 | DOI:10.1016/j.ygyno.2021.05.012

Source: Gynecologic Oncology - May 23, 2021 Category: Cancer & Oncology Authors: Zhuo Ma Ximu Sun Zhixia Zhao Wenchao Lu Qixiang Guo Shihao Wang Jiwen You Yuhui Zhang Lihong Liu Source Type: research